Article
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
EBioMedicine - 1 Oct 2020
Sun Hao, Liu Si-Yang, Zhou Jia-Ying, Xu Jin-Tian, Zhang Huang-Kai, Yan Hong-Hong, Huan Jiao-Jiao, Dai Ping-Ping, Xu Chong-Rui, Su Jian, Guan Yan-Fang, Yi Xin, Yu Rong-Shan, Zhong Wen-Zhao, Wu Yi-Long
Abstract excerpt
BACKGROUND: Although TP53 co-mutation with KRAS/ATM/EGFR/STK11 have been proved to have predictive value for response to immune checkpoint inhibitors (ICIs), not all TP53 mutations are equal in this context. As the main part of TP53 mutant types, Missense and Nonsense alternations in TP53 as independent factors to predict the response to ICIs within Lung Adenocarcinoma (LUAD) patients have not yet been reported....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.